Dataset opportunity
Lipocoat — 监管记录数据集机会
Lipocoat 持有的海量监管记录数据集,可用于监管 RAG 和合规 Copilots。
Score
78.6
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
65%
Action
许可
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球医疗保健监管事务中的人工智能市场 = 2024 年为 12 亿美元,复合年增长率为 16.7%。
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
监管记录数据集
Modality
文本
Sector
医疗保健
Volume
大型
Freshness
定期
Rarity
中等
Accessibility
部分
Legal
公司所有 — 许可权待澄清
Buyer persona
RegTech 和合规 AI 供应商
Lipocoat 持有的监管记录数据集,数据模态为文本,包含专有的化学配方、临床试验数据和监管提交证据。这些结构化和非结构化的工业数据集合非常适合训练监管 RAG 系统,以应对复杂的合规查询并加速产品审批流程。
全球医疗保健监管事务中的人工智能市场凸显了其价值,该市场在 2024 年已达到12 亿美元,并预计将以 16.7% 的复合年增长率增长。虽然访问需要应对围绕专有化学配方以及与特温特大学联合研究相关数据的知识产权敏感性,但该数据集的稀有性和深度为快速增长的人工智能驱动的合规领域提供了显著的竞争优势。⚠ 尽职调查(有价值的数据,可协商的访问权限):临床试验数据涉及监管和隐私限制;专有化学配方是高度敏感的知识产权;数据通常与学术合作伙伴(特温特大学)的联合研究相关 · 公司:独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据共同证明 Lipocoat 持有专业的监管记录和技术文档,详细说明了其医疗涂层技术根据 ISO 10993-1 等标准进行的生物相容性评估。这个基于文本的数据集是RegTech 和合规 AI 供应商培训或增强医疗保健领域复杂性RAG 系统的主要资产。在全球医疗保健监管事务中的人工智能市场预计将在 2024 年达到 12 亿美元,年增长率超过 16% 的背景下,该数据集为自动化合规和产品验证工作流程提供了独特的竞争优势。
See dimension details ↓- Dataset Specificity90
主导的“监管”,医疗保健行业,3 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity58
专有领域数据(开放会降低稀有度)
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume70
6 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness62
API/开放(当前)
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
适合监管 RAG
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
人工智能买家需求旺盛,这得益于在快速增长的全球医疗保健监管事务中的人工智能市场(16.7% 的复合年增长率)中自动化合规和获得预测性见解的需求。
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility68
开放/API 访问
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility84
中等难度,独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength89
5 种证据类型,6 次命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License70
所有权=公司所有,许可=权利不明确
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation56
2 个数据需求信号(2 种类型)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
盈余=高 — 专有数据超出已货币化的部分
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit100
✓ 良好目标 — Lipocoat 是一个理想的目标,因为它是一家开发和制造专有医疗涂料的中小型企业,作为其核心业务的副产品产生了大量的性能、测试和监管数据,而它似乎并未出售这些数据。问题:该公司帮助其合作伙伴收集市场批准和注册数据,这可以被解释为一项服务,但其核心产品仍然是其产品。
- Deep Qualification90
✓ 通过 — Lipocoat 是一个强大的数据持有者目标。它开发和销售专有医疗涂料,产生有价值的监管、临床和配方数据作为副产品。由于广泛的合作伙伴关系,所有权是混合的,虽然没有发现明确的转售限制,但数据是敏感的(临床/GDPR)。最近获得 TFDA 批准是一个强有力的商业触发因素。
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Downloads / exports
可下载的产品手册和数据表的存在提供了关于产品规格和营销声明的结构化文本,这对于与监管提交进行交叉引用至关重要。
API access
关于材料成分和技术规格的结构化数据,例如涂层厚度和特定化学物质的缺失,为自动合规和安全评估提供了可验证的输入。
Regulatory records
直接的文本证据证实该技术已根据 ISO 10993-1 进行了生物相容性测试,代表了用于培训合规模型的核心监管文件。
Image collection
来自图像集合的相关文本详细说明了特定的性能声明,例如增强的超声可见性,这些是验证营销与批准设备功能相关的关键数据点。
Industrial data
该数据集包括工业性能测试的寿命数据,量化了涂层随时间对抗生物膜形成的有效性,并为设备耐用性声明提供了关键证据。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Lipocoat Regulatory Records — a Large regulatory records dataset (Text modality) in the healthcare domain. Primary AI use-case: Regulatory RAG. Market signal: Global AI in Healthcare Regulatory Affairs market = $1.2B in 2024, CAGR 16.7% (source: Transparency Market Research). Investment score 78.6/100 (confidence 0.65). Recommended action: License.
From the marketplace
Explore live data opportunities
C Hafner — 法规记录数据集机会
View opportunity →工业Antaresindustries — 监管记录数据集机会
View opportunity →医疗保健Celonic — 监管记录数据集机会
View opportunity →